These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38386198)

  • 1. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis.
    Schouten TJ; van Goor IWJM; Dorland GA; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; Cirkel GA; van Dam RM; Festen S; Groot Koerkamp B; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; Liem MSL; van Lienden KP; Los M; de Meijer VE; Patijn GA; Schreinemakers JMJ; Stommel MWJ; van Tienhoven GJ; Verdonk RC; Verkooijen HM; van Santvoort HC; Molenaar IQ; Daamen LA;
    Ann Surg Oncol; 2024 Aug; 31(8):4956-4965. PubMed ID: 38386198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
    Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
    J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?
    Nakamura T; Asano T; Okamura K; Tsuchikawa T; Murakami S; Kurashima Y; Ebihara Y; Noji T; Nakanishi Y; Tanaka K; Shichinohe T; Hirano S
    J Gastrointest Surg; 2019 May; 23(5):990-996. PubMed ID: 30242645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
    [No Abstract]   [Full Text] [Related]  

  • 6. Preoperative Prediction of Long-Term Survival After Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
    Konishi T; Takano S; Takayashiki T; Suzuki D; Sakai N; Hosokawa I; Mishima T; Nishino H; Suzuki K; Nakada S; Ohtsuka M
    Ann Surg Oncol; 2024 Oct; 31(10):6992-7000. PubMed ID: 38926210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study.
    van Goor IWJM; Andel PCM; Buijs FS; Besselink MG; Bonsing BA; Bosscha K; Busch OR; Cirkel GA; van Dam RM; Festen S; Koerkamp BG; van der Harst E; de Hingh IHJT; Kazemier G; Liem MSL; Meijer G; de Meijer VE; Nieuwenhuijs VB; Roos D; Schreinemakers JMJ; Stommel MWJ; Wit F; Verdonk RC; van Santvoort HC; Molenaar IQ; Intven MPW; Daamen LA;
    Ann Surg Oncol; 2024 Nov; 31(12):8264-8275. PubMed ID: 38937412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
    de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
    Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
    Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
    J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer.
    Kato Y; Yamada S; Tashiro M; Sonohara F; Takami H; Hayashi M; Kanda M; Kobayashi D; Tanaka C; Nakayama G; Koike M; Fujiwara M; Kodera Y
    HPB (Oxford); 2019 Sep; 21(9):1211-1218. PubMed ID: 30773450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study.
    Jung HS; Han Y; Yun WG; Cho YJ; Lee M; Lee DH; Kwon W; Jang JY
    Int J Surg; 2024 May; 110(5):2883-2893. PubMed ID: 38376856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microscopic resection margin status in pancreatic ductal adenocarcinoma - A nationwide analysis.
    Daamen LA; van Goor IWJM; Schouten TJ; Dorland G; van Roessel SR; Besselink MG; Bonsing BA; Bosscha K; Brosens LAA; Busch OR; van Dam RM; Fariña Sarasqueta A; Festen S; Groot Koerkamp B; van der Harst E; de Hingh IHJT; Intven MPW; Kazemier G; de Meijer VE; Nieuwenhuijs VB; Raicu GM; Roos D; Schreinemakers JMJ; Stommel MWJ; van Velthuysen MF; Verheij J; Verkooijen HM; van Santvoort HC; Molenaar IQ;
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):708-716. PubMed ID: 33323293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study.
    Matsumoto I; Murakami Y; Shinzeki M; Asari S; Goto T; Tani M; Motoi F; Uemura K; Sho M; Satoi S; Honda G; Yamaue H; Unno M; Akahori T; Kwon AH; Kurata M; Ajiki T; Fukumoto T; Ku Y
    Pancreatology; 2015; 15(6):674-80. PubMed ID: 26467797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it justified to assess the resectability of pancreatic cancer combined with biological and conditional factors?
    Huang B; Geng H; Jin Y; Zhang X; Qian H; Ye D; Wu J; Zhu H; Yu Y; Zhou D; Li J
    Transl Cancer Res; 2022 Oct; 11(10):3458-3470. PubMed ID: 36388054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.